Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Bellicum Pharmaceuticals stock (BLCM)

Buy Bellicum Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Bellicum Pharmaceuticals is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the PINK and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 13 staff and has a trailing 12-month revenue of around $1.5 million.

Our top picks for where to buy Bellicum Pharmaceuticals stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

How to buy Bellicum Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BLCM. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Bellicum Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bellicum Pharmaceuticals stock price (PINK: BLCM)

Use our graph to track the performance of BLCM stocks over time.

Bellicum Pharmaceuticals shares at a glance

Information last updated 2024-04-04.
52-week range$0.07 - $0.29
50-day moving average $0.11
200-day moving average $0.26
Wall St. target price$5.00
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.67

Bellicum Pharmaceuticals financials

Revenue TTM $1.5 million
Gross profit TTM $-17,378,000
Return on assets TTM -78.1%
Return on equity TTM -148.5%
Profit margin 0%
Book value $-2.78
Market Capitalization $778,326

TTM: trailing 12 months

Bellicum Pharmaceuticals share dividends

We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.

Have Bellicum Pharmaceuticals's shares ever split?

Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 5 February 2020 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.

Bellicum Pharmaceuticals share price volatility

Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $0.065 up to $0.289. A popular way to gauge a stock's volatility is its "beta".

BLCM.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Bellicum Pharmaceuticals's is 1.382. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bellicum Pharmaceuticals overview

Bellicum Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc. ; BioVec Pharma, Inc. ; ARIAD Pharmaceuticals, Inc.

Frequently asked questions

null
What percentage of Bellicum Pharmaceuticals is owned by insiders or institutions?
Currently 0.987% of Bellicum Pharmaceuticals shares are held by insiders and 32.908% by institutions.
How many people work for Bellicum Pharmaceuticals?
Latest data suggests 13 work at Bellicum Pharmaceuticals.
When does the fiscal year end for Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals's fiscal year ends in December.
Where is Bellicum Pharmaceuticals based?
Bellicum Pharmaceuticals's address is: 3730 Kirby Drive, Houston, TX, United States, 77098
What is Bellicum Pharmaceuticals's ISIN number?
Bellicum Pharmaceuticals's international securities identification number is: US0794814048
What is Bellicum Pharmaceuticals's CUSIP number?
Bellicum Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 079481404

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site